Fair Prescription Drug Prices for Americans Act
- Bill Number
- S. 1587
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-05-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2025-12-05T22:49:35Z
AI-Generated Summary
Purpose
The "Fair Prescription Drug Prices for Americans Act" (S. 1587) aims to lower the cost of certain prescription drugs and biological products in the United States by capping their retail list prices. It does this by requiring U.S. prices to not exceed the average retail list prices in six other countries: Canada, France, Germany, Italy, Japan, and the United Kingdom. The goal is to make these medications more affordable for Americans by benchmarking against international prices.
Key Provisions
- Definitions:
- Biological product: A medicine derived from living organisms, approved under specific sections of the Public Health Service Act.
- Drug: A medication approved under the Federal Food, Drug, and Cosmetic Act.
- Secretary: Refers to the Secretary of Health and Human Services (HHS), the federal official overseeing health policy.
- Price Cap: The retail list price (the manufacturer's suggested price before discounts) for covered drugs and biological products in the U.S. cannot exceed the average retail list price in the six specified countries.
- Price Calculation: HHS must annually compute the average price using:
- Data reported by drug and biological product manufacturers.
- Publicly available filings from manufacturers in those countries.
- Penalties for Violations: Manufacturers that charge above the cap face a civil monetary penalty (a fine) calculated as 10 times the price difference per unit sold. For example, if the U.S. price exceeds the average by $10 per unit, the fine is $100 per unit.
- Data Reporting: Manufacturers must submit annual list prices to HHS for their products in the U.S. and the six countries.
- Implementation: HHS will issue guidance and create regulations to enforce these rules.
Significant Changes to Existing Law
This bill introduces a new system of international reference pricing, where U.S. drug prices are directly tied to averages from other nations—a concept not currently in federal law. It adds mandatory price reporting by manufacturers and civil penalties for exceeding caps, expanding HHS's authority over drug pricing beyond existing programs like Medicare negotiations under the Inflation Reduction Act. No prior U.S. law imposes such a strict international benchmark on retail list prices.
Potential Impacts
- On Citizens: Could reduce out-of-pocket costs for prescription drugs and biological products, benefiting patients with chronic conditions or high healthcare expenses. However, it might indirectly affect drug availability if manufacturers adjust supply or development.
- On Government Agencies: HHS gains new responsibilities for data collection, price calculations, enforcement, and rulemaking, potentially increasing administrative workload and budget needs.
- On International Relations: Relies on pricing data from other countries, which could strain diplomatic ties if those nations view it as interference in their healthcare systems. It might encourage global discussions on drug pricing but could complicate trade negotiations involving pharmaceuticals.
Main Stakeholders Affected
- Drug and Biological Product Manufacturers: Primary targets, as they must report prices, comply with caps, and risk fines; this could squeeze profits and influence pricing strategies.
- Patients and Consumers: Stand to gain from potentially lower prices, especially those without insurance or facing high copays.
- Healthcare Providers and Insurers: May see reduced costs passed on through lower reimbursements, but could face supply disruptions if manufacturers limit U.S. sales.
- HHS and Federal Government: Tasked with oversight, enforcement, and data management.
- Foreign Governments and Manufacturers: Indirectly affected, as their pricing data influences U.S. caps and could lead to retaliatory policies.
Notable Legal, Constitutional, or Political Implications
- Legal: Establishes enforceable price controls via civil penalties, which could lead to lawsuits from manufacturers challenging HHS's calculation methods or data accuracy under administrative law. It builds on existing FDA approval processes but adds a new layer of post-approval regulation.
- Constitutional: May raise questions under the Commerce Clause (which governs interstate trade) if seen as overly burdensome on national pharmaceutical markets, though it aligns with Congress's authority to regulate health and safety. No direct free speech or due process issues are evident, but enforcement could involve First Amendment challenges to price reporting.
- Political: Addresses widespread concerns about high U.S. drug costs compared to other nations, potentially appealing to voters seeking affordability. However, it could face opposition from the pharmaceutical industry, influencing lobbying and future healthcare debates in Congress. If enacted, it might set a precedent for broader international benchmarking in other sectors.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-05-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-05-05: Introduced in Senate
Bill Versions
- Fair Prescription Drug Prices for Americans Act — issued 2025-05-05 — PDF (4 pages)